LEU-001 is under clinical development by Leucid Bio and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LEU-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LEU-001 overview

LEU-001 is under development for the treatment of recurrent head and neck cancer squamous cell carcinoma.  It is administered through intratumoral, intrapleural and intraperitoneal route. The drug candidate consists of autologous T4 positive T-cells acts by targeting Proto Oncogene c ErbB 1.

It was also under development for the treatment of epithelial ovarian cancer and malignant pleural mesothelioma.

Leucid Bio overview

Leucid Bio (Leucid Bio) is a cell therapy firm that develops innovative cell treatments for patients with solid tumors. The company focuses on creating CAR T-cell treatments that induce a stronger and longer-lasting response than prior CAR T generations, allowing doctors to enhance treatment results and save the lives of patients with resistant malignancies. Leucid Bio is headquartered in London, England, the UK.

For a complete picture of LEU-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.